AstraZeneca will face a “substantial setback” if its most ambitious foray into cutting edge immunotherapy falls flat, its chief executive Pascal Soriot has acknowledged.
The eagerly awaited study into a new lung cancer drug is expected to produce its first results within weeks.
> Read the full article on the Financial Times website
By Sarah Neville and David Crow
Source: Financial Times
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.